Terms: = Leukemia AND HOXD11, ENSG00000128713, 3237 AND Treatment
2 results:
1. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract] [Full Text] [Related]
2. Successful treatment of acute myelomonocytic leukaemia with NUP98-hoxd11 fusion transcripts and monitoring of minimal residual disease.
Terui K; Kitazawa J; Takahashi Y; Tohno C; Hayashi Y; Taketani T; Taki T; Ito E
Br J Haematol; 2003 Jan; 120(2):274-6. PubMed ID: 12542486
[TBL] [Abstract] [Full Text] [Related]
